When was Bicycle founded?

Bicycle was founded in 2009 and raised its 1st funding round 1 year after it was founded.

Where is Bicycle located?

Bicycle is headquartered in Cambridge, United Kingdom. It is registered at Lexington, Massachusetts.

Which legal entities is Bicycle associated with?

Bicycle is associated with Bicycletx Limited and 2 others.

How many employees does Bicycle have?

As of May 31, 2026, the latest employee count at Bicycle is 276.

Is Bicycle a funded company?

Bicycle is a funded company, having raised a total of $89.6M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 29, 2010.

When was the latest funding round of Bicycle?

Bicycle's latest funding was a $***** Post IPO round on May 28, 2024, with participation from 6 investors. Its primary sector is Oncology. In United Kingdom, the Oncology sector has seen $448M in funding in 2026 to date.

What is the annual revenue of Bicycle?

Annual revenue of Bicycle is between $50M and $100M as on Dec 31, 2025

Where does Bicycle rank among its competitors?

Bicycle ranks 54th amongst 3261 active competitors, of which 1122 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Bicycle?

Bicycle's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

Bicycle - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of precision-guided therapeutics for targeted cancer therapy. It is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging science to develop a new and differentiated class of medicines to treat cancer and other diseases.

Website: www.bicycletherapeutics.com/
Social
Email ID: *****@bicycletherapeutics.com
Registered Address: Lexington, Massachusetts

Key Metrics

Founded Year

2009

Location

Cambridge, United Kingdom

Stage

Public

Total Funding

$89.6M in 6 rounds

Latest Funding Round

Post IPO, May 28, 2024, $*****

Investors

Vertex Growth & 16 more

Ranked

54^th among 3261 active competitors

Annual Revenue

$50M - $100M as on Dec 31, 2025

Employee Count

276 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 2977 more

Exit Details

Public

View Bicycle's full profile

Bicycle is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BICYCLE THERAPEUTICS INC CIN: 812139178 , United States, Active	Dec 26, 999	-	117 (As on Dec 31, 2024)	-
Bicycletx Limited CIN: 11036101 , United Kingdom, Active	Oct 26, 2017	-	-
BICYCLE THERAPEUTICS PLC CIN: 11036004 , Germany, Active	Oct 26, 2017	$50M - $100M (As on Dec 31, 2025)	79 (As on Dec 31, 2020)

Bicycle got listed on May 23, 2019.

Click here to take a look at Bicycle's IPO in detail

Bicycle has raised a total funding of $89.6M over 6 rounds. Its first funding round was on Apr 29, 2010. Its latest funding round was a Post IPO round on May 28, 2024 for $*****. 6 investors participated in its latest round. Bicycle has 17 institutional investors.

Here is the list of recent funding rounds of Bicycle:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 28, 2024	2895252	Post IPO	2662824	9000648	7576415	3154018
Jan 04, 2018	5665475	Grant (prize money)	3645756	2174314	3107313	Gov
Jun 01, 2017	3169371	Series B	2453716	1117184	Vertex Growth	Longwood Fund & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Bicycle's funding rounds and investors

The founders of Bicycle is Greg Winter. Kevin Lee is the CEO of Bicycle.

Here are the details of Bicycle's key team members:

Greg Winter: Co-Founder & Director of Bicycle.
Kevin Lee: CEO of Bicycle.

Bicycle's Board of Directors

Bicycle's board has 3 active members. Kevin Lee and Michael Skynner are part of team and Mirza Zafar Iskander Qadir is independent board member.

Here is the list of Bicycle's board of directors:

Name	Type	Representing	Status	Duration
ngcwn{c	Team	-	Current	5y 9m
h{dolvv	Team	-	Current	4y 3m
Mirza Zafar Iskander Qadir	Independent board member	-	Current	5y 0m

View details of Bicycle's Founder profiles and Board Members

Bicycle's employee count trend

Bicycle has 276 employees as of May 26. Here is Bicycle's employee count trend over the years:

Uncover Bicycle's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Bicycle include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Bicycle, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Eight Roads Ventures & 23 others	71/100
54th	Bicycle 2009, Cambridge (United Kingdom), Public	Developer of precision-guided therapeutics for targeted cancer therapy	$89.6M	Deep Track Capital, RA Capital Management ... & 15 others	66/100